Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: patients with NAFLD receiving 2 tablets of 200 microgram of chromium picolinate per day for 3 months. Delivery of medication to patients will be done every two weeks and it will be m
Treatment - Other
patients with NAFLD receiving 2 tablets of 200 microgram of chromium picolinate per day for 3 months. Delivery of medication to patients will be done every two weeks and it will be monitored during
Control group:Patients with NAFLD who receive a placebo of corn starch tablets for two days each day for 3 months. Placebo will be delivered to patients every two weeks and will be monitored by the ph
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients who agree to participate in the study Men and women aged 20 to 50 years BMI ranges from 25 to 40 kg / m 2 Increased levels of ALT and AST are higher than normal levels Grade 2, 3, and 4 diseases
Exclusion criteria
Exclusion criteria: kidney disease Thyroid gland problems Uncontrolled blood pressure Taking statin Hepatitis C and B Cytomegalovirus Pregnancy alcohol consumption Wilson Hocromatosis Deficiency of alpha-1 antitrypsin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL. Timepoint: First and three months after the start of the study. Method of measurement: Enzyme colorimetry.;HDL. Timepoint: First and three months after the start of the study. Method of measurement: Enzyme colorimetry.;TNF-a. Timepoint: First and three months after the start of the study. Method of measurement: ELISA Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma Atherogen Index. Timepoint: Study beginning and 90 days after the start. Method of measurement: Triglyceride logarithmic formulation divided by high density lipoprotein.;BMI. Timepoint: First and six weeks after study. Method of measurement: Weight divided by second power of height.;Dietary intakes. Timepoint: First and 6 weeks after the start. Method of measurement: 24-hour dietary recall inventory questionnaire.;Psychological stress. Timepoint: First and six weeks after the start of the study. Method of measurement: Holmes-and rahe scales questionnaire.;Insulin resistance index. Timepoint: First and three months after the study??. Method of measurement: Calculate Homeostatic model assessment.;The amount of physical activity. Timepoint: First and 6 weeks after study. Method of measurement: The International Physical Activity Questionnaire.;Waist circumference. Timepoint: First and Sixth Week. Method of measurement: measurement.;Boddy fat mass. Timepoint: First and Sixth Week. Method of measurement: Bioelectrical impedance analysis.;Blood pressure. Timepoint: Frist and sixth week. Method of measurement: Digital monometer.;Chromium levels of blood. Timepoint: First and 3 months later study. Method of measurement: Spectrophotometry.;SOD. Timepoint: First and three months after the start of the study. Method of measurement: Biochemical kit.;ALP. Timepoint: First and three months after the start of the study. Method of measurement: Biochemical kit.;AST. Timepoint: First and three months after the start of the study. Method of measurement: Biochemical kit.;Resistin. Timepoint: First and three months after the start of the study. Method of measurement: ELISA Kit.;Leptin. Timepoint: First and three months after the start of the study. Method of measurement: ELISA Kit.;MAD. Timepoint: First and three months after the start of the study. Method of measurement: Biochemical kit.;GPX. Timepoint: First and three months after the start of the study. Method of measurement: | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBahram Pourghasem Gargari
Tabriz University of Medical Sciences
Outcome results
None listed